四磨汤超微饮片联合TACE治疗原发性肝癌临床观察

Clinical study of ultramicro-powder of Simo decoction combined with TACE for primary liver cancer

目的观察四磨汤超微饮片联合导管动脉化疗栓塞术(TACE)治疗原发性肝癌的临床疗效。方法将60例原发性肝癌患者随机分为超微组(四磨汤超微饮片联合TACE治疗)、汤剂组(四磨汤汤剂联合TACE治疗)、对照组(TACE治疗)。其中超微组剂量为汤剂组剂量1/2,两组口服给药。观察3组近期的客观疗效、生存质量、不良反应发生率。结果超微组、汤剂组、对照组疾病控制率分别为75%、65%、65%,差异无统计学意义(P>0.05)。超微组、汤剂组与对照组治疗后生活质量改善比较差异有统计学意义(P<0.05)。超微组、汤剂组恶心呕吐、肝区疼痛、发热发生程度与对照组比较,差异有统计学意义(P<0.05)。结论四磨汤超微饮片联合TACE治疗原发性肝癌有较好的临床疗效,能减少不良反应,改善患者生活质量。

Objective To study the clinical efficacy of ultramicro-powder of Simo decoction combined with TACE for primary liver cancer to treat the liver cancer.Methods All the 90 patients with primary liver cancer were randomly divided into ultramicro-pow der group,traditional decoction group and control group treated with TACE.The differences of recent curative effect,the living quality and the incidence of adverse reactions.Results The disease control rate in the powder group,decoction group and control group were 75%,65% and 65% respectively,there were no significant differences（P〉0.05）.The difference of life quality improved after treatment between the powder group and the decoction group was statis tically significant（P〈0.05）,and compared with control group,the symptoms of nausea,vomiting,liver pain and fever in powder group and the decoction group were reduced（P〈0.05）.Conclu sions Simo decoction ultramicro-powder combined TACE is effective for primary liver cancer and can decrease adverse reaction and improve the patients＇ life quality.